Pharmaceutical · Fiscal year end Mar 31

NIPPON CHEMIPHAR CO., LTD.

4539

日本ケミファ株式会社

FIGI BBG000BG72D54539.T4539 JPCorp. no. 5010001033101

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-13

For the first half of the fiscal year to 2026-03: Revenue ¥15.9 billion (+2.0% YoY), Ordinary income ¥0 billion, Net income ¥0.2 billion.

	This period	Year on year
Revenue	¥15.9bn	+2.0%
Ordinary profit	¥48m	—
Net profit to owners	¥163m	—

From the securities report on EDINET, which states no forecast. History via /v1/companies/4539/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31

Revenue: ¥33.1bn
Net income: ¥198m
ROE: 1.0%
Equity ratio: 39.0%
Dividend / share: ¥50
Employees: 878

Revenue · ¥bn

Net income · ¥m

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥33.1bn	¥0.2bn	¥50.0bn	¥19.5bn	1.0%	¥54.81	¥0.6bn
2025-03-31	¥32.6bn	¥0.3bn	¥49.9bn	¥19.2bn	1.6%	¥81.72	−¥0.3bn
2024-03-31	¥30.7bn	−¥0.2bn	¥49.5bn	¥18.5bn	-1.0%	¥-50.14	¥0.3bn
2023-03-31	¥31.6bn	¥0.3bn	¥48.6bn	¥18.5bn	1.8%	¥94.07	−¥0.9bn
2022-03-31	¥32.5bn	¥0.7bn	¥49.5bn	¥18.5bn	3.8%	¥194.33	¥1.8bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	1	8.3
Ordinary margin	0.0069	11.3
Equity ratio, %	39	25.3
Revenue growth	0.016	32.1
Net income growth	-0.3265	17.6
Operating cash flow / assets	0.0124	20.4

Policy-uncertainty measure0.75 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Regulation 1 Politics & geopolitics 1

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 7.3% held by other listed companies.

Results wording balance: +0.43. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥15.4bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥77m, 12.4% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4539/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-06-15: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Segments: Medicine, Other. /v1/companies/4539/segments

Latest voting result: 2026-06-17 · 剰余金処分の件 · passed. /v1/companies/4539/voting

Ownership changes

All companies →

2026-08-05

Increase+1.02pt

Japan Sopharcim CO., LTD raised holdings in NIPPON CHEMIPHAR CO., LTD. (4539) to 21.48% from 20.46%.

S100YQCNFiler profile Original filing (PDF, Japanese)
2025-12-05

Decrease−7.03pt

Japan Sopharcim CO., LTD reduced holdings in NIPPON CHEMIPHAR CO., LTD. (4539) to 20.46% from 27.49%.

S100X7NQFiler profile Original filing (PDF, Japanese)
2025-12-05

New 5% stake

Yamaguchi Scientific Promotion Public Interest Incorporated Foundation disclosed a 7.04% stake in NIPPON CHEMIPHAR CO., LTD. (4539), crossing the 5% reporting threshold.

S100X7X7Filer profile Original filing (PDF, Japanese)
2025-08-08

Increase+2.84pt

Japan Sopharcim CO., LTD raised holdings in NIPPON CHEMIPHAR CO., LTD. (4539) to 27.49% from 24.65%.

S100WGW3Filer profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
ジヤパンソフアルシム株式会社	2025-12-05 – 2026-08-03	+9,600	+0.18pt	¥1,624.05	¥1,555–1,712
公益財団法人山口記念科学振興財団	2025-12-05 – 2025-12-05	0	0.00pt	—	—
individual filer	2025-08-08 – 2025-08-08	+84,800	+1.99pt	¥1,507	¥1,507–1,507

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4539/trades.

5% filings

Large shareholding reports on 4539

Filed	Filer	Stake	Change	Stated purpose
2026-08-05	Japan Sopharcim CO., LTD	21.48%	+1.02pt	management participation
2025-12-05	Japan Sopharcim CO., LTD	20.46%	−7.03pt	management participation
2025-12-05	Yamaguchi Scientific Promotion Public Interest Incorporated Foundation	7.04%	—	—
2025-08-08	Japan Sopharcim CO., LTD	27.49%	+2.84pt	management participation

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 11 issues
Book value: ¥1.7bn
Sold in the year: ¥206m 1 issues
Bought in the year: — — issues
Mutual, both reports: 6
Held by listed cos.: 12

Holds	Book value	Shares vs. prior year	Mutual
Tokyo Kiraboshi Financial Group, Inc. 7173	¥670m	0.0%	both reports
ZERIA PHARMCEUTICAL CO., LTD. 4559	¥379m	0.0%	both reports
Alfresa Holdings Corporation 2784	¥146m	0.0%	both reports
Mizuho Financial Group, Inc. 8411	¥140m	0.0%	no
Hokuhoku Financial Group, Inc. 8377	¥88m	0.0%	no
Delta-Fly Pharma㈱	¥83m	0.0%	no
SUSMED, Inc. 4263	¥56m	0.0%	no
Astena Holdings Co., Ltd. 8095	¥47m	0.0%	both reports
TOHO HOLDINGS CO.,LTD. 8129	¥37m	0.0%	both reports
㈱ほくやく・竹山ホールディングス	¥33m	0.0%	no

Held by: ZERIA PHARMCEUTICAL CO., LTD. 4559, Tokyo Kiraboshi Financial Group, Inc. 7173, FUKUDA DENSHI CO.,LTD. 6960, Daito Pharmaceutical Co., Ltd. 4577, ASAHI KOGYOSHA CO.,LTD. 1975, Astena Holdings Co., Ltd. 8095, Alfresa Holdings Corporation 2784, VITAL KSK HOLDINGS,INC. 3151, TOHO HOLDINGS CO.,LTD. 8129, TSUMUGU Holdings, Inc. 3055, SUZUKEN CO.,LTD. 9987, Aozora Bank, Ltd. 8304

Purposes, all holdings and mutual flags via /v1/companies/4539/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
ジャパンソファルシム株式会社	433,000	11.88%
公益財団法人山口記念科学振興財団	300,000	8.22%
豊島薬品株式会社	242,000	6.63%
日本生命保険相互会社	144,000	3.94%
individual holder	126,000	3.45%
日本ケミファ従業員持株会	122,000	3.35%
ゼリア新薬工業株式会社	121,000	3.32%
上田八木短資株式会社	118,000	3.25%
individual holder	110,000	3.04%
individual holder	104,000	2.87%

Get this as JSON

GET /v1/companies/4539
GET /v1/companies/4539/financials
GET /v1/companies/4539/details
GET /v1/companies/4539/segments
GET /v1/companies/4539/voting
GET /v1/companies/4539/tender-offers
GET /v1/companies/4539/indicators
GET /v1/companies/4539/earnings-releases
GET /v1/events?ticker=4539
GET /v1/companies/4539/trades         
GET /v1/companies/4539/cross-holdings 
GET /v1/companies/4539/brief

Plans from $9 a month · Documentation